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INTRODUCTION
Styrene (CAS No. 100-42-5), a derivative of benzene, is a widely used industrial chemical, obtained for industrial use from petroleum and natural gas by-products (Helal and Elshafy, 2012) . The International Agency for Research on Cancer (IARC) Monograph Volume 82 (IARC, 2002) describes the major uses of styrene in the manufacture of materials, including glass fiber-reinforced composites, polystyrene products, styrene-alkyd coatings, and styrenebutadiene synthetic rubber. The wide variety of consumer products that involve styrene in their production includes boats, bathtubs, showers, food packaging, automotive reinforced plastics and body putty, foams and cushioning materials for packaging, disposable tableware, latex paints, and synthetic marble flooring. Human exposure to styrene is primarily occupational with the highest exposures found in industries making consumer products from glass fiberreinforced polyester composite plastics (IARC, 2002) . Perhaps the greatest nonoccupational exposure source for styrene is from cigarette smoke, with smokers having exposure levels approximately six times higher than nonsmokers (IARC, 2002) .
The main metabolite of styrene is styrene 7,8-oxide (SO; CAS No. 9609-3) (see Fig. 1 ), which results from oxidation by cytochromes P450 (Watabe et al., 1978; Vainio et al., 1981 Vainio et al., , 1984 Hynes et al., 1999; IARC, 2002; Vodicka et al., 2006) . SO is hydrolyzed to styrene glycol (CAS 93-56-1) by epoxide hydrolase. Additional metabolites of styrene include mandelic acid (MA), phenylglyoxylic acid (PGA), benzyl alcohol, benzoic acid, and hippuric acid (Sugiura and Goto, 1981; Vainio et al., 1981) .
IARC, the National Toxicology Program (NTP), and the National Academy of Sciences (NAS) have reviewed the available data and assessed the carcinogenicity of styrene. IARC has published three Monographs on the carcinogenicity of styrene (IARC, 1979 (IARC, , 1994 (IARC, , 2002 and one Monograph on SO (IARC, 1985) . The 2002 IARC Monograph classifies styrene as possibly carcinogenic to humans (Group 2B) based on the limited evidence in both humans and rodents. At its recent March 2018 meeting, IARC upgraded styrene to be a Group 2A carcinogen, "probably carcinogenic to humans, based on limited evidence in humans and sufficient evidence in experimental animals" (IARC, 2018) . In 2008, the NTP published a summary review document as a background information to assist with its styrene carcinogenicity review (NTP, 2008) . In 2011, in its 12th Report on Carcinogens, the NTP listed styrene as "reasonably anticipated to be a human carcinogen." The NAS was tasked with conducting an independent review of this assessment. In 2014, the National Research Council (NRC) of the National Academies Press published a document "Review of the Styrene Assessment in the National Toxicology Program 12 th Report on Carcinogens" (NRC, 2014) . Based on their review of the available studies, the NRC committee concluded that the NTP classification for the carcinogenicity of styrene was appropriate. This cancer classification was based on limited evidence in humans and sufficient evidence in experimental animals. Because of the relevance of genotoxicity information in the overall weight-of-the-evidence for the mode of action (MOA) for a carcinogen, the IARC Monographs (IARC, 1979 (IARC, , 1985 (IARC, , 1994 (IARC, , 2002 , the NTP background document (NTP, 2008) , and the NRC report (NRC, 2014) all include summaries of the extensive literature, dating to the 1970s, concerning the genotoxicity of styrene and SO, from in vitro assays and in rodents in vivo. These summaries are based directly on the individual study author determinations and include both positive and negative results.
After these reviews were published, the Organization of Economic Cooperation and Development (OECD) made substantial revisions to the genotoxicity test guidelines (TGs), and these revisions affect the conduct of assays and the interpretation of test results (OECD, 2017; Thybaud et al., 2017) . In addition, there have been a few recent publications addressing the potential genotoxicity of styrene/ SO. It is, therefore, timely to critically review (based on current OECD recommendations) the evidence as to whether styrene is mutagenic/clastogenic, either in vitro or in rodents in vivo, or both.
It is recognized that many early studies were conducted prior to the development of any TGs and that the results of many of these studies may not be reliable. Although other studies may have met the guidelines in place when they were conducted, experience with the assay may have resulted in new recommendations for assay conduct and interpretation of data. In some cases, this new insight for assay conduct and interpretation means that older results can no longer be interpreted, or results that may have been considered positive (or negative) would no longer be considered definitive results. To provide optimal information concerning the mutagenicity/clastogenicity of a widely studied compound, it is important to critically review the available information and to utilize only high-quality data in the overall weight-of-the-evidence evaluation. The goal of this critical review is to consider each study and determine whether an individual study was designed and conducted using procedures compliant with the current TGs and whether the published dataset can be interpreted as positive or negative. Based on this curated database, we then provide a critical assessment of the mutagenicity/clastogenicity of styrene and SO. The focus of our critical review is on assays for which there are OECD TGs and for endpoints most directly related to addressing the question as to whether styrene can induce gene mutations. Because they can provide supporting information concerning chemical exposure and the ability of chemicals to cause primary DNA effects, literature information for additional endpoints such as DNA adducts and DNA strand breakage is summarized, but it is not critically reviewed. In addition to providing this updated information for styrene, this review demonstrates how the new OECD guidance can be applied to chemicals that have large (older) genetic toxicology databases, where many of the study results may or may not be reliable.
LITERATURE SEARCH AND SUMMARY OF PREVIOUS REVIEWS
With the goal of conducting a critical review of the available published studies to address the mutagenicity/clastogenicity of styrene and to summarize the information from other genotoxicity endpoints, a PubMed literature search was performed using the following search terms:
(Styrene OR "Styrene oxide" OR "Mandelic acid" OR "4-vinylphenol" OR "1-phenylethanol" OR "Phenylgloxylic acid") AND ("Genetic Damage" OR Genotoxicity OR "Ames Test" OR "Salmonella typhimurium" OR "E. Coli Mutation" OR "Chromosome Aberration" OR "Sister Chromatid Exchange" OR "DNA Adduct" OR "DNA Damage" OR "DNA breakage" OR "DNA breaks" OR "Single Strand breaks" OR Micronucleus OR "Gene Mutation" OR "hprt Mutation" OR "Mouse Lymphoma Assay" OR "Thymidine Kinase Mutation" OR "Transgenic Mutation Assay" OR "Genetic Toxicology" OR Mutation OR Mutagenesis OR Clastogenicity OR Aneuploidy OR Polyploidy OR Mutagenicity OR "Comet Assay" OR Comet OR "Single Cell Gel" OR "Alkaline elution").
All abstracts returned from the PubMed search were reviewed to identify relevant references for evaluating the genotoxicity of styrene. It was clear from the initial review of the abstracts that many of the papers did not actually contain genetic toxicology information and thus they were easily eliminated from further consideration in this first step. Any genetic toxicology relevant literature cited in the IARC Monographs (IARC, 1985 (IARC, , 1994 (IARC, , 2002 and the NTP Review (NTP, 2008) but not identified in the PubMed search was added to the list of papers to be considered in the review.
The literature search identified several peer-reviewed journal summary/review articles for styrene. Many of these (particularly the older summaries) simply reported the conclusions (positive/negative calls) of the publication authors with little, if any, critical review of the individual studies Norppa and Vainio, 1983; Norppa et al., 1988; Bond and Bolt, 1989; Barale, 1991) . In 2002, The Harvard Center for Risk Analysis conducted a comprehensive (12-member international expert panel) review of the potential human health effects of styrene exposure (Cohen et al., 2002) . The panel concluded that styrene "does not appear to be DNA reactive", but SO clearly induces mutations in the Ames test. SO binds to both proteins and nucleic acids and forms both stable N 2 and O 6 guanine adducts in exposed mammalian cells. The panel concluded that the results in animal studies are "less clear cut," with conflicting results as to whether styrene can cause sister chromatid exchanges (SCEs), chromosome aberrations (CAs), or micronuclei (MN) in rodents.
The first detailed critical review of studies, considering study/data quality and evaluating styrene's cytogenetic effects (in vitro, in vivo, and in occupationally exposed humans), was conducted by Preston, 1994a, 1994b) and includes summary data tables with extensive details. Their review of the in vitro data for styrene and SO resulted in a conclusion that both chemicals can induce CAs and SCEs but that positive results are dependent upon test conditions that favor metabolic activation of styrene to SO over inactivation of SO. They found "no convincing" evidence that in vivo styrene exposure can cause chromosome damage in rodents. For the in vivo studies showing positive results for clastogenicity, they reported that the positive response was only seen at lethal doses and via intraperitoneal (i.p.) injection (now considered to be an inappropriate route, per OECD TG475 [OECD, 2016a] ). The positive response was not observed via inhalation in Chinese hamsters or after oral exposure (also an inappropriate substitute for the inhalation route) in mice. SCEs were seen in rodents from in vivo exposure to both styrene and SO but only at very high concentrations.
A decade later, in 2005, Leigh Henderson and Gunter Speit published a critical review of the in vivo rodent genetic toxicology assays. They concluded that there was no clear evidence that styrene induces clastogenic/mutagenic effects in vivo when the test is performed under appropriate test conditions (Speit and Henderson, 2005) . They also concluded that "equivocal" results can be observed when the tests were performed using high exposure levels that led to lethality. Also, in 2005 , Nestmann et al. (2005 provided an overview of reviews that had been previously conducted. They concluded that rodent studies at exposures up to 1500 mg/m 3 (352 ppm) per day showed no evidence of clastogenicity.
STRATEGY FOR CRITICALLY REVIEWING THE MUTAGENICITY/CLASTOGENICITY OF STYRENE
The available literature evaluating the potential mutagenicity/clastogenicity of styrene and SO exposure includes most, but not all, of the standard in vitro mammalian cell and rodent in vivo tests for which there are OECD TGs. We note that in the recent OECD revision process, all the genetic toxicology TGs were considered for revision or deletion (OECD, 2017; Thybaud et al., 2017) . The TGs for several assays were archived/deleted. Reasons for deletion included that the assays are rarely used, the underlying mechanisms for the endpoints that they measure are not fully characterized or are no longer considered relevant, or because other assays are considered more relevant for assessing genotoxicity. There are styrene and/or SO data for many of these test systems and this information has been summarized in previous reviews, including the IARC and NTP documents. However, because the results from these tests are no longer considered relevant for new testing for identifying potential human risk, information from these tests was not included in our current review. Table I lists the OECD TGs that were deleted.
Although the in vitro SCE TG was deleted, and data for the in vitro assay were not included in our review, results from the in vivo SCE assay were included. It should be noted that, in the past, the SCE assay was extensively used in both human and rodent studies and there are data for many different chemical exposures (Latt et al., 1981; Tucker et al., 1993) . Extensive research to understand the mechanistic basis, and the significance of SCEs, ultimately led to the conclusion that the two sister chromatids broke and rejoined with one another, physically exchanging DNA segments, but that the process was error free (Wilson and Thompson, 2007) . That is, SCEs are not actually reflective of genetic damage. This was the basis for deleting the in vitro SCE OECD TG. Data from the in vivo SCE assay can be useful as a biomarker of exposure, assessing the ability of test materials to reach target tissues. However, positive results observed with the SCE endpoint should not be considered evidence that a chemical is genotoxic.
Weight-Of-The-Evidence Interpretation of the Various Types of Results
There are several endpoints/assays providing useful information for assessing whether a chemical, such as styrene, can cause genetic damage. Endpoints can be classified by the broad term "genotoxicity" or the more restrictive term "mutagenicity." It is ultimately the ability of a test material to induce mutations, which is the most important. Although many slightly different definitions of the terms genotoxicity and mutagenicity exist, the definitions considered in this critical review are those provided in the OECD Overview to the recent revisions of the TGs (OECD, 2017): Genotoxicity is a broader term. It includes mutagenicity (described above), and it also includes DNA damage which may be mutagenic, but may also be reversed by DNA repair or other cellular processes, and, thus, which may or may not result in permanent alterations in the structure or information content in a surviving cell or its progeny.
The broader set of genotoxicity tests that do not, however, provide definitive information that the test material is mutagenic include primary DNA damage tests such as unscheduled DNA synthesis (UDS), DNA strand breaks, the Comet assay, and DNA adduct formation. Written to provide background information and a summary of the TG revisions, the OECD Overview document (OECD, 2017) provides a context for these types of assays and clearly states that more weight should be given to the results from tests that measure permanent DNA changes (i.e., mutations) than to DNA damage events that can be reversible. Primary DNA damage tests are useful for preliminary screening and can be useful in some types of mechanistic studies, such as an assessment of oxidative DNA damage and/or MOA assessment for cancer in specific target tissues. They can also serve as an exposure biomarker for in vivo studies to determine whether a test chemical and/or its metabolites can reach a specific target tissue and interact with DNA. Ultimately the goal in evaluating the potential for a test material to induce genetic damage is to determine if the material actually induces mutations. This can only be assessed using gene mutation assays. The chromosomal damage endpoints (CA and MN) do not actually measure mutations, as most of these events are not compatible with cell survival. However, the underlying events that cause microscopically visible chromosome damage and MN also cause mutation.
Relevant Recommendations from the Revised OECD TGs
The recently revised OECD TGs for the standard genetic toxicology assays provide improved guidance concerning assay conduct, acceptance criteria for individual test results, and an overall strategy for interpreting test data (positive/negative). A publication by Thybaud et al. (2017) and an OECD document entitled "Overview of the set of OECD Genetic Toxicology Guidelines and updates performed in 2014 -2015 " (OECD, 2017 provide details concerning the deliberations upon which the revisions were based and an overview of the most significant changes from previous versions of the TGs. TG471 for the Ames test was not revised and therefore there are no new considerations for the interpretation of data from this assay. While the major revisions occurred in the 2014-2015 versions of the TGs, minor administrative changes were made in 2016; the overview document was adopted in 2016 with minor administrative changes in 2017.
Of particular importance in interpreting previously published data for chemicals such as styrene and SO are the new recommendations for the in vitro mammalian assays concerning the appropriate top level of cytotoxicity (which should not be exceeded), the appropriate top concentration in the absence of cytotoxicity (which should not be exceeded), and the incorporation of the historical range of the spontaneous background levels, in interpreting whether a response is positive or negative. New cytotoxicity and concentration limits were established to ensure that any observed positive responses were biologically relevant, not simply resulting from excess cytotoxicity. In addition, to ensure appropriate statistical power, there are new recommendations for the number of cells that should be scored for the cytogenetic assays, the minimum number of cells that should be treated, maintained during the phenotypic expression, and cloned for mutant enumeration in gene mutation assays. For the cytogenetic assays, the historically scored number of cells (particularly for the older studies) often meant that the actual number of background events was too low to be accurately measured. It was difficult to determine if a small increase in the number of events in the treated group was, in fact, different from the background. Furthermore, random variability might result in an inaccurately high (or low) level of scored events in the background of one or more of the treated groups, thus characterizing responses as positive or negative that were not representative of the actual level of events. For the in vitro mammalian gene mutation assays, in which mutations are rare events (occurring as a few mutants per million cells), it is important to treat, carry, and sample enough cells to obtain an accurate value for the mutant frequency. Most of the cytogenetic and hypoxanthine-guanine phosphoribosyltransferase (hprt) gene mutation studies (particularly the older studies) conducted to evaluate styrene/ SO utilized less (often much less) than the currently recommended number of cells.
The new recommendations for determining whether a test chemical is positive or negative bring into consideration the distribution of the historical negative controls. This is done in recognition of the fact that there is biological variability in the background levels of the various endpoints and that the use of even duplicate or triplicate cultures for in vitro assays and five animals per dose point for in vivo assays does not provide a mean value that is the actual mean of the distribution of values that would be obtained had a larger number (10-20 or more) of replicates been technically feasible to use. That is, the full extent of the random variation is not captured in a single experiment. This is especially an issue when the concurrent negative control falls at the low end of the historical control distribution, resulting in random increases in responses being characterized as positive responses. Furthermore, there is a chance (one in 20) when a statistical probability of 0.05% is used that a treated group will be statistically different from the concurrent negative control, when, in fact, there is really no difference. Based on these considerations, the general recommendation in the revised TGs requires that the following three criteria all be met for a clear positive response: (1) "at least one of the test conditions exhibits a statistically significant increase compared to the concurrent negative control," (2) "the increase is concentration-related when evaluated with an appropriate trend test," and (3) "any of the results are outside the distribution of the historical negative control data (e.g., Poissonbased 95% control limit)." A clear negative response would require that none of these three criteria are met. Of course, applying these criteria (particularly, the third criterion) to published data can be problematic, as there is very rarely any information on historical background ranges in a published paper, but the criteria can serve as a general basis for expert interpretation of data. That is, statistically different, but very small, increases above the concurrent negative control may not actually be reflective of a positive response and should not be considered definitive evidence that the response is positive.
CRITICAL REVIEW OF THE INDIVIDUAL STUDIES FOR STYRENE/SO
In the following sections, a concise description is provided for each of the evaluated endpoints and its relevance to understanding whether styrene and/or SO are mutagenic. For this critical review, individual publications were examined to determine the technical conduct of the assay, to assess whether the approach presented in the publication is consistent with current recommendations, and how the data presented in the publication should be interpreted. An overall weight-of-the-evidence assessment is then provided for the overall database for each endpoint. Starting with the endpoints that are the most relevant for assessing the potential for styrene/SO to induce mutation (gene mutation, CA, and MN), the review details are presented below. As already indicated, the data for endpoints that assess exposure are not critically reviewed but are briefly summarized.
Assays that Assess Gene Mutation
As discussed in the OECD Overview document (OECD, 2017) , assays that evaluate the potential for chemicals to cause gene mutation are the most relevant for determining the ability of chemicals to cause genetic damage that will be compatible with cell survival and, therefore, of potential consequence to the whole organism. In vitro gene mutation assays routinely used for hazard identification include the bacterial Ames test and assays using either the Tk or hprt genes in mammalian cells. Data for styrene/SO were identified using all three of these routine in vitro assays. Although in vivo gene mutation assays are available using hprt or transgenes in rodents, no such data were identified for styrene/SO.
AmesTest (TG471B87)
Starting as early as 1976, many investigators have studied the ability of styrene, SO, or other styrene metabolites to induce reverse mutations (point mutations) in a number of different Ames tester strains (OECD, 1997a) . Many of these studies were conducted prior to the 1997 (current) OECD TG471 in which specific strains were recommended. Therefore, not all the currently recommended strains were included in these early studies. This has no impact on studies in which the results were positive, as only one strain needs to be positive for the overall result to be positive. However, it does mean that negative results reported for studies using less than the full set of strains should not be considered definitive. In addition, many of the older publications do not have the level of detail that is currently expected or that allows a full evaluation of the methods used. This prevents determining whether the studies were conducted in a way that would be fully compliant with TG471 (OECD, 1997a). Many of the older studies did not routinely include positive control chemicals to demonstrate that the assay, particularly the exogeneous activation system, was working properly. However, the Ames test has generally been conducted according to the methods that were originally published by Bruce Ames and, unlike some of the other genetic toxicology tests, the methods and the interpretation of data have not changed substantially over the years. Therefore, unless there were specific reasons to question the methodology of a specific paper, it was assumed for purposes of this evaluation that the methods used in the various publications were generally OECD TG compliant. We considered a response to be positive if there was at least a two-fold increase (three-fold for strains with low backgrounds) in the observed number of revertants, above the background.
The majority of Ames test studies used SO as the test material. A concise summary of these individual studies, in chronological order, is provided in Table II . In addition to the publications which provided Ames test data that could be evaluated for this review, there are publications that include study summaries for large numbers of chemicals and only indicate positive/negative mutagenicity results for styrene and/or SO. Table III lists these publications and includes the (limited) summary information presented in the publications.
Only a small subset of the Ames test studies used styrene as the test material. Many of these studies were designed to address questions such as metabolism, the mutagenicity of styrene metabolites, and/or the methods for exposure, and De Flora et al. (1984) Plate incorporation TA97, TA98, TA100
Commercial source, purity 99% Positive in TA97 and TA100 (without S9; tested between 100-1,000 μg/plate). Note that the paper has conflicting statements as to whether their results were positive or negative Brams et al. (1987) Styrene Oxide Plate incorporation TA1535
No information on purity or source Positive (described as a weak positive; without S9) McCann et al. (1975) and McCann and Ames (1976) Plate incorporation TA100, TA1535
97% purity
Positive Wade et al. (1978) Suspension TA100, E. coli WP2uvrA
Analytical grade
Positive in both strains (without S9) Hemminki and Falck (1979) Plate incorporation G46, TA98, TA100, TA1530, TA1535, TA1538
Commercial source, no information on purity Positive in TA100 (without S9) Bartsch et al. (1980) Preincubation De Flora et al. (1984) Environmental and Molecular Mutagenesis. DOI 10.1002/em the methods used were nonstandard. These studies are summarized below in chronological order. Vainio et al. (1976) evaluated styrene in strains TA98, TA100, TA1535, TA1537, and TA1538, both with and without S9, prepared from male Sprague Dawley rat liver, following induction with Clophen C. A data table from a preliminary screening, using concentrations 0, 10 −8 , 10 −7 , and 10 −6 mol/plate, indicates that the number of revertants in TA1535 (with S9) were 16, 112, 84, and 16, respectively; in TA100 (without S9) were 83, 115, 56, and 197, respectively; and in TA100 (with S9) were 97, 163, 78, and 206, respectively. A more detailed presentation of results is graphically provided in the publication, for the evaluation in TA1535 (with S9). Eight concentrations between 10 −9 and 10 −6 were used and there is clearly a dose-response increase that exceeds the background by at least two-fold, in the 10 −9 to 10 −8 concentration range, followed by a drop in the number of revertants per plate, likely due to toxicity. Based on this publication, styrene (both with and without S9) is weakly mutagenic in TA100 and clearly mutagenic (with S9) in TA1535. Styrene glycol was also evaluated (with S9) and was nonmutagenic.
Milvy and Garro (1976) evaluated a series of styrene metabolites (SO, styrene glycol, D-and L-MA, PGA, benzyl alcohol, benzoic acid, and hippuric acid) using the spot test version of the Ames test. The test was conducted using TA98, TA100, TA1535, TA1537, and TA1538. In this screening assay, only SO was positive, and these positive results were seen in TA100 and TA1535.
de Meester et al. (1977) provided data indicating that styrene is not mutagenic (strains TA98, TA100, TA1535, TA1537, and TA1538) without S9 activation at concentrations between 1 and 100 μM/plate. A positive response was observed in test strain TA1535 with Aroclor-1254-induced male Wistar rat liver S9. Fifteen different concentrations of styrene from 1 to 15 μM/plate were evaluated. The assay was conducted using a protocol that determined cytotoxicity based on % bacterial survival, thus demonstrating a clear dose-responsive increase in cytotoxicity. The number of revertants per plate increased from a background of 14 AE 3 to 136 AE 19 at a concentration of 11 μM/plate. It should be noted that this top concentration resulted in a 5% survival for the bacteria; however, a positive response was observed at multiple lower, and less cytotoxic, concentrations. These authors also investigated whether the mutagenicity of SO would be altered with S9. Without S9, SO was mutagenic (in strains TA100 and TA1535) within a range of 100 nM/ plate to 20 μM/plate. With S9, higher SO concentrations were required (from 4 to 60 μM/plate) to observe a positive response, suggesting a decrease in mutagenicity related to SO metabolism. Although the data for styrene were tabulated, the data for SO were only presented graphically; however, it was clear that the SO response exceeded two-fold above background and demonstrated a dose-response. The authors speculated that the lower response for SO exposure with S9 might be due to further metabolism of SO to styrene glycol which is known to be nonmutagenic in TA1535.
Using both the spot test and the plate incorporation method, Stoltz and Whitey (1977) evaluated styrene, with Aroclor 1254-induced rat and hamster liver S9, in strains TA98, TA100, TA1535, TA1537, and TA1538. They used styrene concentrations up to one milligram per plate and found the results to be negative. Watabe et al. (1978) presented a series of experiments investigating the mutagenicity of styrene in strains TA98, TA100, TA1535, TA1537, and TA1538. As their primary goal was to investigate the metabolism of styrene, they used S9 mixes prepared from Wistar rat livers that were induced using several different inducing agents (3-methylcholanthrene [3-MC], phenobarbital [PB] , and polychlorinated biphenyls [PCBs]). Gas chromatography (GC) was used to evaluate the conversion of styrene to SO and styrene glycol with the different S9 mixes under the same conditions that were used for the mutation experiments but without the presence of the bacteria. The authors tested styrene in the presence of PCB-induced S9 up to a concentration of 500 μg/plate in the five strains and found no increase in the number of revertants for any of the strains. From the data presented in Table I of the publication, it appears that the 500 μg/plate concentration was cytotoxic to all strains except for TA100. To further investigate the potential mutagenicity of styrene, experiments were conducted using S9 mixes prepared from all the above listed inducers and in the presence of 1,1,1-trichloro-2,3-propene oxide (TCPO), an inhibitor of epoxide hydratase which would be expected to prolong the half-life of any SO that was produced by the S9 metabolic activation. For these experiments, the Ames test was conducted using TA100. To obtain a mutant frequency, the number of revertants were expressed per surviving bacteria rather than as the number of revertants per plate. Only two concentrations of styrene (three and six millimolar) were used. There was no increase in the mutant frequency for the uninduced S9 or the PCB-induced S9. The six millimolar styrene concentration coupled with PB-induced or 3-MC-induced S9 caused an increase in the mutant frequency (83 and 477 induced mutants per 10 8 surviving bacteria, respectively). In both cases, however, this increase in mutant frequency occurred at very high levels of cytotoxicity (9% and 6% survival, respectively). It should be noted that the Ames test is not normally conducted in a way to quantify the level of cytotoxicity and, therefore, there is no recommended maximum level of cytotoxicity. If one were to apply the 10% level recommended for the mammalian cell gene mutation assays, then it would be concluded that these results were not biologically relevant. To further investigate the response with the 3-MC-induced S9, the authors conducted additional experiments using TA100 and four millimolar of both styrene and SO, with and without the addition of TCPO. With 3-MC S9 and TCPO, the four millimolar styrene exposure yielded a survival of 30% and an induced mutant frequency of 91 per 10 8 surviving bacteria. SO, conversely, showed an induced mutant frequency of 235 per 10 8 surviving bacteria (at 51% survival), which was not observed with the addition of 3-MC S9 alone (87% survival) or the addition of both 3-MC S9 and TCPO (84% survival). These last two treatment conditions showed induced mutant frequencies of 17 and 54 per 10 8 surviving bacteria, respectively. The GC analysis showed that the SO formed during the styrene treatment was rapidly inactivated to styrene glycol. The addition of TCPO prolonged the half-life of SO, as expected. When the analysis was conducted using the variously induced S9 mixes, it was determined that the highest accumulation of SO occurred in the presence of the 3-MC-induced S9 plus TCPO and that the lowest accumulation was with the PCBinduced S9 plus TCPO. Watabe et al. (1978) also evaluated the mutagenicity of 1-vinylbenzene 3,4-oxide (styrene 3,4-oxide) in TA100, T98, and TA1537. Although they only used four concentrations with S9 (the highest of which was cytotoxic based on a downturn in the dose-response curve), there was an overall positive dose-response and at least a doubling of the number of revertants per plate in TA100. Busk (1979) evaluated styrene using strains TA98, TA100, TA1535, TA1537, and TA1538, and a concentration range of 10 −3 -15 μM/plate, with and without S9, and found styrene to be negative. With the goal of modifying the metabolic activation for styrene, S9 preparations were made from the livers of Aroclor 1254-and Clophen C-induced rats. In addition, two metabolic inhibitors, including TCPO and diethyl maleate (to inhibit glutathione conjugation), were added to the S9/styrene exposure. This strategy was an attempt to prevent further metabolism of any SO that might be formed by the S9 metabolic activation system. In all cases, styrene was found to be nonmutagenic.
de Meester et al. (1981) speculated that poor solubility and the volatility of styrene may contribute to the divergent results that had been reported for styrene. They conducted a study in which plates containing the bacteria and S9 were placed in a desiccator filled with either styrene or SO mixed with air for a 24-hr exposure. Strains TA100, TA1530, and TA1535, exposed to 24% (v/v) styrene in air, all showed an increase in the number of revertants per plate that, based on a visual analysis of the graphic data, appear to be at least twice the background number of revertants. Graphical dose-response data are presented for TA1530 for five concentrations (2666-13,330 ppm) of styrene, and there does appear to be a positive doseresponse, which plateaus (at 8000 ppm) and then declines at 13,300 ppm. Exposure to 24% (v/v) SO in air was also mutagenic to the same three strains with a similar system. The presence of S9 lowered the number of revertants per plate compared to what was observed with the SO exposure alone.
Considering all the available Ames test data, including the very large number of SO studies, it is clear that styrene via SO metabolism is mutagenic, in vitro, in the Ames test.
In Vitro Mammalian Gene Mutation Assays
The in vitro mammalian cell gene mutation assays for which either styrene or SO data are available include the mouse lymphoma thymidine kinase (Tk) assay (often called the mouse lymphoma assay [MLA]) and the hprt assay. hprt assay data were identified using exposure to V79 cells, two human lymphoblastoid cell lines, and primary human T-lymphocytes. Brief details of the publications including a summary of the methods and results as well as our critical review and overall interpretation of the individual study data are provided in Table IV . A description of both of the in vitro mammalian gene mutation assays and weight-ofthe-evidence conclusions as to whether styrene/SO can induce mutations in mammalian cells are as follows.
MLA using the Tk gene (TG490). The MLA, using L5178Y TK +/− 3.7.2C cells, detects a wide spectrum of genetic events, including both single gene mutations and viable chromosomal events (including chromosomal rearrangements, deletions, and mitotic recombination; OECD, 2016b). To evaluate the full array of mutational events, careful attention must be paid to the optimal quantification of all the mutants, both small and large colony mutants. The MLA has historically been a part of OECD TG476 (OECD, 2016c). A new TG (TG490) was written to incorporate specific internationally agreed upon recommendations for use in the conduct and interpretation of data from this assay (OECD, 2016b). These recommendations include criteria for defining an acceptable assay based on ensuring optimal mutant colony growth, as well as the use of a global evaluation factor in the interpretation of data (positive/negative). For styrene, no studies using the MLA were identified. Amacher and Turner (1982) evaluated SO for its ability to induce mutation in the MLA, with and without S9 metabolic activation. The protocol was not compliant with OECD TG490, because the methods used to grow and count the mutant colonies were suboptimal. That is, only a subset of the mutants (the large colony mutants) was counted, thus losing the ability to detect the small colony mutants. However, without S9, SO was clearly positive (using current data interpretation criteria [the global evaluation factor]) based solely on the large colony Tk mutant response. With S9, the response is clearly different from the response without S9 and was not positive. The cytotoxicity of the SO was much lower without S9 than with S9; substantially higher concentrations of SO were needed to attain a cytotoxicity level (based on relative total growth) between 10% and 20% without S9. Despite the deficiencies in the assay conduct, we concluded that SO without S9 was mutagenic in the MLA. (Table II) . Uninterpretable. Loprieno et al. (1976) HPRT-V79 cells Methods indicated as that of Loprieno et al. (1976) . The focus of the study was to examine expression time. (Shield and Sanderson, 2004) were reasonably welldetailed and it was possible to determine that sufficient cells were exposed and an appropriate expression time and selective agent were used. In the second paper (Shield and Sanderson, 2001) , an insufficient number of cells were treated. In both studies, based on the graphical presentation of the data, the cell lines deficient in GSTM1 showed a greater degree of cytotoxicity (assessed by % population growth over eight days) and higher mutant frequency than the cell lines expressing GSTM1 activity.
Not OECD TG476 compliant. The recommended cytotoxicity method for assessing the appropriateness of concentration selection was not used in either study making it impossible to determine if appropriate concentrations (per TG476) were used. Uninterpretable. Sanderson (2001, 2004) Gene mutation assays using the hprt gene (TG476). The hprt assay detects primarily gene mutations, including point mutations and small-scale deletions; however, there is evidence that some larger deletions can be detected (OECD, 2016c) . New recommendations for conducting the assay include ensuring that a sufficient number of cells are used for appropriate statistical power and to reduce variability that can result from using insufficient cell numbers to quantify rare events. The new recommendation is that 20 million cells be treated and no less than 2 million be present during expression and mutant selection. Two studies evaluating styrene and nine studies evaluating SO for its ability to induce hprt gene mutation in cultured mammalian cells were reviewed (see Table IV ). Most studies were published prior to the mid-1980s. Many of the publications did not provide an adequate description of the methods. For many papers, it was not possible to determine how many cells were used. No publications were identified that used methods consistent with the current recommendations. Several of the publications presented data only in graphic form that was impossible to evaluate. Deficiencies (at least two) were identified in every study and therefore, based on this published information, it is not possible to determine whether styrene or SO is mutagenic in the in vitro hprt assay.
Weight-Of-The-Evidence: Does Styrene/SO Induce Gene Mutations InVitro?
For the Ames test, there are studies for styrene exposure that give positive results and studies that give negative results. Some investigators attributed at least part of the differences to the technical aspects of evaluating a volatile chemical. However, the underlying cause for these differences may simply be based on differences in the metabolic system(s) that were used in the various studies. Based on the literature, it is unclear whether unmetabolized styrene is mutagenic. However, it is clear that SO is mutagenic in the Ames test. Overall, the Ames test results indicate that when styrene is metabolized to SO, it is positive in the Ames test. Most of the positive results for SO exposure were obtained without exogenous metabolic activation and, thus, the SO is not further metabolized. There is a balance between the activation of styrene to SO and the detoxification of SO, and the end result for a particular study depends upon this balance Norppa and Vainio, 1983) . In the section above, several studies designed to provide insight into styrene metabolism and Ames test results are described.
For the in vitro mammalian cell gene mutation studies, none of the assays using the hprt locus were interpretable, based on at least two deficiencies in every study. Although the single MLA study had technical shortcomings, it was possible to identify SO as mutagenic. Thus, based on this single study, we conclude that SO is capable of inducing gene mutations in mammalian cells in culture. As there were no interpretable studies on styrene, no conclusion can be drawn as to whether unmetabolized styrene can cause gene mutation in mammalian cells in culture.
Although there are several methods and an OECD TG for evaluating in vivo induction of gene mutation, there were no studies identified for rodents treated in vivo with either styrene or SO and evaluated for the induction of gene mutation.
Assays that Assess Chromosomal Damage
There were several publications identified in which the authors evaluated styrene or SO for the ability to induce CA or MN, with either in vitro or in vivo exposures. Unfortunately, many of the in vitro studies were conducted and published prior to the recognition that excessive cytotoxicity can result in biologically irrelevant positive responses for the CA and MN assays (Lorge et al., 2008; OECD, 2017) , and the introduction of the requirement to include an appropriate measure of cytotoxicity in the experimental design.
CA Assays
CAs are microscopically visible alterations to chromosomes. They include visible breaks, deletions, and rearranged sections of chromosomes. There are standard recommendations as to how they should be scored and reported. Gaps (defined as a nonstaining region of the chromatid with minimal misalignment of that chromatid) should be scored and reported but not considered in the decision as to whether the test chemical can induce chromosome breakage. It is important to note that some of the older studies included gaps or other nonstandard events in the reported values.
CAs in cultured mammalian cells (TG473). As previously discussed, the revised TG for this assay incorporates new recommendations for appropriate measures of cytotoxicity, maximum levels of cytotoxicity, top concentration in the absence of cytotoxicity, and data interpretation (OECD, 2016d) . In addition, the number of metaphases recommended for scoring (per test concentration) has been increased to 300 from the numbers recommended in previous TGs. Four studies for styrene and seven studies for SO have been reported and are summarized chronologically in Table V . Only one of the studies met the criteria of the revised TG which would allow for its interpretation as a positive or negative study. The Jantunen et al. (1986) study shows that when there is metabolic capability, styrene can induce CAs in mammalian cells in culture. The details and rationale for judging this study as positive are as follows. Jantunen et al. (1986) used cultured human lymphocytes (both with and without erythrocytes) to evaluate the ability of styrene to induce CAs. The erythrocytes were added to Environmental and Molecular Mutagenesis. DOI 10.1002/em Mitotic index data not presented.
Not OECD TG473 compliant. The lack of an appropriate concurrent measure of cytotoxicity, scoring of events that are not currently normally scored and the use of a single concentration make this experiment uninterpretable. Linnainmaa et al. (1978a Linnainmaa et al. ( , 1978b CHL cells Methods not fully described. Scoring included polyploid cells in addition to structural aberrations. Mitotic index data not presented.
Not OECD TG473 compliant. The lack of an appropriate concurrent measure of cytotoxicity, scoring of events that are not currently normally scored and the use of a single concentration make this experiment uninterpretable. Linnainmaa et al. (1978a Linnainmaa et al. ( , 1978b CHL cells A single concentration (2.4 mM or 0.25 mg/mL) for styrene treatment was presented.
No measure of cytotoxicity.
While no measure of cytotoxicity was used in the study, which evaluated a number of chemicals, it is clear from the text that concentrations were used for many of the test materials that resulted in no metaphases. Although the incidence of CAs was clearly much higher (and clearly positive) with S9 activation than without, it is not possible to determine the level of cytotoxicity attained in this culture. Not OECD TG473 compliant. The lack of an appropriate concurrent measure of cytotoxicity, and only a single concentration make the experiment uninterpretable. Matsuoka et al. (1979) CHL cells More than 400 chemicals were tested. Pohlová et al. (1984) Environmental and Molecular Mutagenesis. DOI 10.1002/em provide metabolic capability. The response with styrene was clearly positive (a clear dose-dependent increase) in the whole blood cultures with a weaker positive response in the lymphocyte cultures that did not include erythrocytes. As a measure of cytotoxicity, the authors used mitotic index which is acceptable for use with lymphocytes in primary cultures (per the 2016 version of TG 473). The data are fully tabulated in the publication, thus allowing for a full review of the information. Five concentrations ranging between 0.5 and 6 mM styrene were used for the study. The top concentration was clearly too cytotoxic to give reliable results, but the four millimolar culture had an appropriate level of cytotoxicity and was clearly positive (19 AE 3.0 aberrations per 100 cells compared to the untreated control, which contained 2.0 AE 0 aberrations per 100 cells). In the experiment investigating exposure to lymphocytes without erythrocytes, there were only two concentrations (one and two millimolar) of styrene with acceptable levels of cytotoxicity. The one millimolar concentration was positive (4.5 AE 0.5 aberrations per 100 cells compared to the untreated control 1.5 AE 0.5). The higher two millimolar styrene concentration showed substantial variability and, therefore, it is less clear as to whether, without the erythrocytes, there is a positive response. It should be noted that the authors only scored 200 cells per concentration compared to the currently recommended 300 cells per test concentration. The increase from 200 to 300 cells for scoring was made to increase statistical power and to decrease statistical variability; the fact that the authors scored only 200 cells may have contributed to the high variability in the two millimolar, without erythrocytes, result. Given that the response in the whole blood cultures is clearly well above the concurrent background, it can be concluded that styrene is clastogenic in vitro.
In vivo rodent CAs (TG475). CAs are generally evaluated in bone marrow cells of exposed rodents (OECD, 2016a). There are some studies for styrene in which lymphocytes were evaluated; however, lymphocytes are technically more difficult and historically have been used much less frequently than bone marrow cells. The new OECD recommendation is that 200 metaphases be evaluated per animal. There were eight studies identified that included CA evaluation following exposure to styrene and three studies for SO exposure. The key details for these studies are summarized in Table VI . In evaluating the relevance of a specific study, route of exposure is important. Inhalation is the most relevant exposure route for both styrene and SO. Six inhalation studies were identified for styrene and one for SO. For styrene, there was one study that used oral exposure and one study that used i.p. injection. For two of the SO studies, the route of exposure was i.p. injection. It should be noted that the new OECD TGs for in vivo genetic toxicology studies consider i.p. to be an irrelevant route of exposure. Of the 11 styrene/SO studies, 9 were uninterpretable because of noncompliance with OECD TG475 (OECD, 2016a) with all having multiple deficiencies (see Table VI ). Reasons for noncompliance included using less than the recommended three treatment doses, fewer than the recommended number of animals per treatment group, no assessment of toxicity, insufficient number of cells scored, and the use of the i.p. route of exposure. For the two remaining studies (both using repeated inhalation exposure to styrene), the only deficiency was that less than the recommended 200 metaphases per animal were scored. Overall, these two studies were negative. Thus, based on these two studies, there is no evidence that inhalation exposure to styrene can induce CAs in vivo in rodents.
Weight-of-the-evidence: Does styrene/SO induces CAs?. Considering all the published studies for styrene/SO, in which CA induction was evaluated as an endpoint, one in vitro mammalian study indicates that, when there is metabolic capability included, styrene can induce CAs in mammalian cells in culture. The weight-of-the-evidence from the in vivo rodent studies indicates that repeated inhalation exposure to styrene does not induce CA.
MN Assays
The MN endpoint can be used to evaluate the ability of a test chemical to induce both chromosome breakage and aneuploidy. Historically, MN have been evaluated by microscopic analysis and most of the studies conducted with styrene/SO (in vitro and in vivo) have used manual microscopic scoring. More recently, new automated techniques have been developed using image analysis or flow cytometry to score MN which provide an easy way to evaluate more cells for higher statistical power, providing a more rigorous evaluation of the test material. One of the in vivo SO inhalation studies (Gate et al., 2012) used the flow cytometric scoring method.
MN in cultured mammalian cells (TG487). As previously discussed, the revised TG for this assay incorporates new recommendations for new methods of analysis, appropriate measures of cytotoxicity, maximum levels of cytotoxicity, top concentration in the absence of cytotoxicity, and data interpretation (OECD, 2016e) . No studies were identified using styrene exposures, and four studies were identified for SO exposure (summarized chronologically in Table VII ). There were two studies that provided interpretable data, and both studies provide evidence that SO can induce MN in cultured mammalian cells. These two studies and the basis for our conclusion are described below. Laffon et al. (2001) used whole blood cultures from two male and two female human donors to evaluate SO induction of MN using the cytokinesis-block method. Cells were exposed to 10, 20, 50, 100, or 200 μM SO. Scoring for the presence of MN was accomplished using 1000 binucleated cells per individual per test concentration. Cytotoxicity was Speit et al. (2012) used the CBPI MN assay and whole blood cultures to evaluate the clastogenicity/aneugenicity of SO in human lymphocytes. As the study was conducted after the approval of TG487, the methods used for the experiments were based on the recommendations in that guideline. No exogenous metabolic activation system was used. Based on the graphical data presented in the publication, it can be concluded that SO was positive for the induction of MN.
In vivo rodent MN (TG474). As with CAs, MN have historically been evaluated in bone marrow cells of exposed rodents, typically mouse (OECD, 2016f). Lymphocytes can also be evaluated but are technically more difficult and historically have been used much less frequently than bone marrow cells. There are two studies (Kligerman et al., 1992 (Kligerman et al., , 1993 for styrene in which lymphocytes were evaluated. More recently, peripheral blood erythrocytes have been evaluated using the flow cytometric method as described above, thus providing more statistical power and in addition allowing rats to serve as test animals. The new OECD recommendation is that 4000 cells be scored per animal.
There were 10 studies identified that included MN evaluation following in vivo exposure to styrene and four studies for in vivo SO exposure. The key details for these The number of MN appears to be substantially higher in the single treated culture than in the control culture.
Not OECD TG487 compliant. Although the number of MN in this culture appears to be substantially higher than the number of MN in the control culture, the lack of an appropriate cytotoxicity measure and the fact that only one concentration is presented make the study uninterpretable. Turchi et al. (1981) Whole blood cultures from two male and two female donors Cytokinesis-block method. Cells were exposed to 10, 20, 50, 100, and 200 μM SO. Scoring for the presence of MN was accomplished using 1,000 binucleated cells per individual per test concentration. Cytotoxicity was assessed using CBPI (an OECD TG487 compliant method for cytotoxicity using lymphocytes).
All of the cultures were within the acceptable cytotoxicity range. The background frequency varied from 3 to 18 MN/1,000 cells and in all cases a clear induction of MN was observed in the cultures treated with SO.
OECD TG487 reasonably compliant (number of cells scored less than the current recommendation). Positive. Laffon et al. (2001) Whole blood cultures from 20 individuals Whole blood cultures were exposed to SO (0.1, 0.2, or 0.3 mM), and 1,000 cells were scored for the presence of MN.
No difference in the MN frequency controls and treated.
Not OECD TG487 compliant. Because there was no measure of cytotoxicity the results are uninterpretable. Godderis et al. (2006) Whole blood cultures (from health male or female nonsmokers) 500, 600, and 750 μM SO exposure. Cytokinesis-block method. The study was designed to compare the addition of CytoB 2 hr after the initiation of exposure to whole blood cultures and at the start of exposure 1,000 cells scored per culture. The nucleus division index (i.e., the replicative index) was used as measure of cytotoxicity.
Data presented graphically. Clearly positive when tested using the standard in vitro assay.
OECD TG487 compliant. Positive. Speit et al. (2012) Environmental and Molecular Mutagenesis. DOI 10.1002/em studies are summarized in Table VIII . Of the 14 total studies, 10 were considered uninterpretable because of noncompliance with OECD TG474 (OECD, 2016f). Reasons for noncompliance included less than the recommended number of exposure levels, fewer than the recommended number of animals per treatment group, insufficient number of cells scored, and the use of the i.p. route of exposure. Studies that were judged to be noncompliant included multiple deficiencies. For inhalation, the most relevant route of exposure for both styrene and for SO, three studies reasonably compliant with OECD guidelines were identified for styrene exposure and one study identified for SO exposure. For the two Kligerman styrene studies (Kligerman et al., 1992 (Kligerman et al., , 1993 , the one deficiency was that less than the currently recommended 4000 cells per animal were scored. Overall these two studies were negative. One inhalation study using both styrene and SO exposures (Gate et al., 2012) was well conducted using flow cytometric scoring of 20,000 cells, and it was possible to conclude that neither styrene nor SO exposure induced MN. Thus, we conclude that there is no evidence that styrene/SO is clastogenic/aneugenic in vivo in rodents via inhalation exposure.
Weight-of-the-evidence: Does styrene/SO induce MN? There were no interpretable in vitro studies in which styrene itself was evaluated. The Laffon et al. (2001) and the recent study by Speit et al. (2012) , conducted using the OECD TG487 (OECD, 2016e), provides definitive evidence that SO can induce MN in vitro in mammalian cells. Although the currently recommended number of cells were not scored, two studies (Kligerman et al., 1992 (Kligerman et al., , 1993 using inhalation exposure to styrene provide evidence that it is negative in vivo in rodents. The recent inhalation study conducted by Gate et al. (2012) provides definitive evidence that neither styrene nor SO induces MN in vivo in rats.
Assays that Detect Exposure
There are several assays/endpoints (SCE, adducts, UDS, and DNA strand breakage) that are useful to detect exposure, but do not provide any definitive proof that a test chemical can induce mutations. With the exception of the in vivo UDS (TG486; OECD, 1997b) and the in vivo Comet assay (TG489; OECD, 2016g), there are no OECD guidelines for these endpoints, thus there are no standard, internationally agreed, approaches for measurement of these biomarkers of exposure. These assays and the available information for styrene/SO are described briefly below.
In Vivo Rodent SCE
No OECD TG for the in vivo SCE assay was ever drafted and approved. A few general principles from the other in vivo TGs can, however, be applied, such as number of animals per test group, number of exposure levels, number of cells scored, and considering the i.p. route of exposure to not be relevant. The reviewed studies are briefly summarized in Table IX . Eight studies were identified and reviewed for styrene exposure. Of these eight, five were conducted using inhalation exposure and three using i.p. Only one of the studies (Kligerman et al., 1993) was found to be wellconducted and to provide evidence that inhalation exposure to styrene can cause the induction of SCEs in peripheral blood lymphocytes in rats. Of the three studies conducted for SO, two used the inhalation route of exposure and one used i.p. All three studies had multiple deficiencies which made the results uninterpretable.
As already discussed, the induction of SCEs is not indicative of the induction of genetic damage but rather an indication of exposure.
Information from Assays that Detect Primary DNA Interaction/Damage
Assays for primary DNA interaction/damage, including DNA adducts, can be conducted using noncellular approaches, cells in culture, and in vivo rodents (or other animals). These endpoints demonstrate exposure of the analyzed tissue to the chemical of interest, provided there is no endogenous/background source. While human relevance increases as one moves from the noncellular to in vitro, to in vivo, the biological relevance of the DNArelated endpoints stays the same. They all provide an indication that a test material can interact with the DNA of the analyzed tissue, but because the various primary DNA interactions/damage can be repaired, these tests/endpoints do not provide any definitive proof that the test material actually induces mutations (OECD, 2017) . In fact, specific DNA adducts have different properties and different potential for effects (Jarabek et al., 2009; Pottenger et al., 2014) . Indeed, certain DNA adducts have been demonstrated as nonmutagenic (Philippin et al., 2014; Pottenger et al., 2018) . Thus, DNA adducts, DNA strand breakage, and UDS are all, like the SCE endpoint, biomarkers of exposure. Protein adducts, although not indicative of DNA exposure, are useful systemic exposure biomarkers. The in vitro UDS OECD TG was eliminated in 2014, and the in vivo UDS assay was strongly considered for deletion but ultimately was retained (but not revised), because there are some jurisdictions that recommend it as a follow-up assay for positive results in the standard in vitro assays. However, the recommendation to retain this TG was primarily made because of limited alternatives (OECD, 2017) .
Protein adducts. SO has been shown to react with nucleophilic sites on plasma proteins and hemoglobin (Hb) to form SO-albumin and SO-Hb adducts; styrene will not react with these moieties without activation. Many groups have developed methods to measure alkylated Hb Conner et al. (1982) and other plasma proteins as biomarkers of exposure to styrene/SO; these methods are now fairly routine and are used to conduct biomonitoring of workers. Although the Hb adducts from SO will be present as α and β structural isomers (see explanation below), there has not been much reported on this aspect for Hb adducts from SO exposure; thus, this aspect is not addressed in the following brief summary of data. Styrene and SO exposure results in alkylation of the amino acid residues at the N-terminal of proteins. Generally, cysteine is the most reactive amino acid and results in formation of S-(2-hydroxy-1-phenylethyl) cysteine in albumin. Alkylation of Hb by styrene/SO results in formation of N 0 -(2-hydroxy-1-phenylethyl) valine and N 0 -(1-hydroxy-2-phenylethyl) valine adducts in Hb (Hemminki, 1986; Basile et al., 2002) . Rappaport et al. (1993) found that reaction rates of SO with Hb and albumin were higher in the rat than in humans. In rodents, both styrene and SO exposures result in the formation of cysteine adducts in albumin and Hb (Ting et al., 1990; Rappaport et al., 1993) , adducts with side chain carboxylic acid residues in Hb (Sepai et al., 1993) and N-terminal valine adducts in Hb (Osterman-Golkar et al., 1995) . Bergmark et al. (1990) identified Nterminal valine and carboxylic acid phenylethyl adducts in purified human Hb treated in vitro with [ 3 H]SO. Rappaport and Yeowell-O'Connell (1999) found that SO was more effective at producing albumin adducts than styrene after inhalation exposure. Derivatized SO-Hb adducts were measured using GC/MS techniques in Hb obtained from male Fischer rats repeatedly exposed to styrene via inhalation (Latriano et al., 1991) . A clear linear dose-response has been shown in both animal and human studies (Pauwels et al., 1996; Liu et al., 2001) at styrene and SO concentrations that do not overload the detoxification process (Osterman-Golkar et al., 1995) . It should be noted that the formation of protein adducts is not an assay for genotoxicity, nor evidence for mutation.
DNA adducts. DNA adducts represent chemically bound moieties to the DNA of cells or tissues. They are detected as modified DNA bases, deoxynucleosides, or oligonucleotides. All four DNA bases can form adducts; Figure 2 depicts the styrene oxide-related binding sites for the nucleic acids. Although some DNA adducts are specific to individual chemicals, others are not, such as those formed from reactive oxygen species (e.g., ). DNA repair, which actively occurs with most DNA adducts, affects the life-span of adducts as does their chemistry. For example, chemically unstable adducts (e.g., N3-adenine and N7-guanine adducts) have half-lives from hours to about three to five days. Following their depurination (spontaneous removal of the unstable adducted base), an apurinic (AP) site is left that can be mutagenic but generally is very rapidly repaired ( Three useful reviews on styrene-related DNA adducts are available. Phillips and Farmer (1994) focused on styrene and SO, while in 2000, Koskinen and Plná (2000) published a "mini-review" of specific DNA adducts that are induced by mono-substituted epoxides, including styrene. The more recent Vodicka et al. (2002) review provides a thorough discussion of SO-induced DNA adducts and information on their potential effects. Because of the unique chemistry of styrene/SO, the DNA adducts formed present a complicated array. This section focuses on the adducts formed by binding of the metabolite SO, the predominant reactive metabolite of styrene, which can bind to DNA via either the 1-phenylethyl or the 2-phenylethyl position, giving rise to either alpha-or beta-structural isomers (Fig. 3) . Theoretically, each of these isomers can form at any of the nucleophilic sites on DNA bases (Fig. 2) . The chemistry is further complicated by the presence of the chiral carbon in SO, which results in either the R or S enantiomer. Thus, at each nucleic acid binding site available for adduction on DNA, the SO moiety is either α or β, and each of those isomers is bound as either R or S, which is not always determined. Figure 3 shows how some of these structures differ. The nomenclature can vary considerably among authors, also depending on the analyte being measured (e.g., nucleic acid vs. nucleoside vs. nucleotide). In order to simplify for this brief review, the following streamlined nomenclature will be used: the structural isomer will be identified, if known (e.g., α or β), preceded by the enantiomeric designation, if known (R or S); the atom bound will be named with its corresponding nucleic acid base atom number (e.g., N7)-endocyclic atoms are italicized and exocyclic atom numbers are superscripted (e.g., O 6 ); SO to represent the 7,8-styrene oxide moiety; and the letter for the particular nucleic acid base (e.g., G, A, C, or T). A few examples are shown below:
The amount of information obtained on specific SOinduced adducts depends on the methods used to generate the samples and the methods used to analyze the samples. The former affects the proportion of each specific adduct formed as the availability of the binding sites (therefore the resulting adduct distribution profile) depends in part on what form of DNA is the target: naked DNA being reacted directly with SO (noncellular), or DNA of cells in culture (in vitro), or DNA in tissues from whole animal exposures to styrene or SO (in vivo). A wider variety of adducts are found for SO-treated naked DNA, whereas tissues from in vivo exposures result in much lower adduction rates and reduced numbers of sites adducted. Another layer of complexity depends on the methods used to identify the adducts. The two most common methods are (1) 32 P-postlabeling, a method that enzymatically attaches a 32 P label to the 5 0 -position of a nucleotide-3 0 -phosphate (both modified and nonmodified), which is then separated either by thin layer chromatography (TLC) or by high-pressure liquid chromatography (HPLC), and chromatographed with standards to identify what adducts are present; and (2) chromatography (often HPLC) coupled with tandem mass spectrometry (MS/MS), which provides structural information to confirm the adduct structure, and allows for quantification. Although 32 P-postlabeling can be very sensitive, it requires special modifications to include the predominant DNA adduct, N7-SO-G Hemminki, 1988a, 1991a; Kumar et al., 1997) , which is a significant drawback; this method does not provide structural confirmation information. The capability to obtain important structural confirmation is only available with techniques that rely on MS/MS.
The kind of structural detail and adduct distribution profiles described above can be critical in consideration of MOA, as different adducts have different capabilities vis-àvis genotoxic effect, ranging from nonmutagenic (e.g., lowmolecular-weight N7-alkyl/hydroxyalkyl-G adducts) (Philippin et al., 2014; Pottenger et al., 2018) to promutagenic if not repaired (e.g., O 6 -alkyl-G adducts) (ibid). Of course, formation of an adduct does not provide any definitive evidence for mutation. Indeed, the adduct represents the first step in a MOA for a mutation that has many steps and off-routes, such as requiring cell replication to permanently incorporate Environmental and Molecular Mutagenesis. DOI 10.1002/em a change in base sequence, which may or may not result in a change in amino acid sequence upon translation (Pottenger and Gollapudi, 2010) . In fact, there is a ubiquitous background of endogenous DNA adducts, including pro-mutagenic ones, present in every cell (Nakamura et al., 2014) , although no specific SO adducts have been identified as endogenous to date.
The numerous available studies using noncellular systems demonstrate convincingly that SO reacts with DNA mainly to form guanine adducts, typically in the following order quantitatively: N7-SO-G >> N 2 -SO-G > O 6 -SO-G adducts (Savela et al., 1986; Pongracz et al., 1989 Pongracz et al., , 1992 Kumar et al., 1997; Siethoff et al., 1999) ; Vodicka and Hemminki, 1988a , 1988b , 1991a Yang et al., 2005) . These have also been identified in animal and human cells/tissues, with in vitro and in vivo studies. Although N7-SO-G is the major adduct formed in the in vitro reaction of SO with DNA, due to the high nucleophilicity of the N7 position, SO adducts have been identified from all the nucleic acid bases. Savela et al. (1986) reported that N7-SO-G adducts accounted for 82% of the SO-induced DNA adducts formed in naked DNA treated with SO. Several in vitro studies (Qian and Dipple, 1995; Koskinen and Hemminki, 1999; Kim et al., 2000) all found N1and N 6 -SO-A adducts. In a study designed to assess both mutation induction and DNA adducts, Bastlová et al. (1995) found that although there was a significant correlation between SO concentrations and formation of DNA adduct levels ( 32 P-postlabeling), there was no correlation between SO-induced hprt gene mutations in human T-lymphocytes and levels of DNA adducts measured. However, it should be noted that there were deficiencies in the hprt evaluation (see gene mutation section above).
As the most relevant exposure route, in vivo styrene inhalation exposure studies evaluating DNA adducts in rodents confirm the formation of many of the same SOinduced DNA adducts identified with in vitro and noncellular systems; several studies are briefly summarized below. As expected, the highly nucleophilic N7-G site clearly predominates with in vivo formation of N7-SO-G. SO-induced DNA adducts have been detected in animal blood, urine, lung, liver, and other tissues of styrene-exposed animals. Latriano et al. (1991) found N7-, N 2 -, and O 6 -SO-G in DNA isolated from the lung and livers of styrene-exposed rats using 32 Ppostlabeling. Also with 32 P-postlabeling, coupled with TLC and extraction techniques, Otteneder et al. (1999) confirmed the formation of α and βO 6 -SO-G adducts in the livers of female rats chronically exposed via inhalation to styrene. Following a single inhalation exposure of mice and rats to [ 14 C] styrene and using HPLC/LSC, Boogaard et al. (2000) found adducts in whole liver (α and βN7-SO-G, N 2 -SO-G, and O 6 -SO-G), whole lung, and lung Clara cells (mainly N7-SO-G), which varied between mice and rats. Koskinen et al. (2001a Koskinen et al. ( , 2001b reported βN1-SO-A DNA adduct formation after repeated inhalation exposure of male NMRI mice to styrene by 32 P-postlabeling. Vodicka et al. (2001 Vodicka et al. ( , 2006 confirmed the formation of N7-SO-G and βN1-SO-A DNA adducts in mouse lung and liver with 32 P-postlabeling and HPLC analyses after repeated exposure to styrene via inhalation. Using HPLC, TLC, and 32 P-postlabeling, Otteneder et al. (2002) evaluated O 6 -SO-G adduct loads in mouse and rat lung and liver (rat only) tissues following repeated inhalation exposure to styrene (chronic and shorter term). The authors identified α and βO 6 -SO-G adducts in liver DNA, but levels in lung tissue were below detection. The researchers concluded that the levels of DNA adducts were detectable in rat liver (nontarget organ), but not in the mouse lung (target organ), thus did not correspond with tumor incidence. Mikeš et al. (2009) confirmed formation of N7-SO-G and α and βN3-SO-A DNA adducts in mouse urine after repeated inhalation exposure to styrene, concluding these adducts were likely rapidly depurinated and eliminated.
UDS (TG486). The UDS assay (OECD, 1997b) is used for the detection of DNA damage/repair activity. The in vivo rodent UDS is generally conducted in the liver and the methodology is well-established (measurement of incorporation of [ 3 H]-labeled thymidine during damage-induced DNA synthesis). There are a few publications involving exposure to styrene or SO and assessment using the UDS assay either in vitro or in vivo; these are summarized here. Brouns et al. (1979) exposed freshly isolated rat hepatocytes to SO and found no evidence of DNA repair activity in the cells. Pero et al. (1982) exposed human lymphocytes in culture to styrene (10-750 μM for 15 min) and concluded that the UDS response was negative. In 1989, Williams et al. (1989) reported positive results for styrene exposure from a UDS validation study on 300 chemicals using rat hepatocytes treated in vitro and assessed for DNA repair to evaluate genotoxicity. Clay (2004) exposed mice by inhalation to concentrations of styrene ranging from 160 to 1000 ppm and evaluated DNA repair in the liver.
He concluded that the observed negative response was consistent with a nongenotoxic MOA for mouse lung tumors. One criticism of this Clay study is that MOA evaluations should be conducted using the target tissue, which would be mouse lung in this case.
DNA strand breakage. There are several techniques that have been used to detect DNA strand breakage. These include alkaline elution, DNA unwinding, and the Comet assay. Of these techniques, only the in vivo alkaline Comet assay has an OECD TG (TG489; OECD, 2016g); there is no TG for the in vitro Comet assay. Although not included in the TG, and therefore without any standard procedure or interpretation, the addition of formamidopyrimidine (FAPy) DNA glycosylase (FPG) allows for the detection of certain oxidative adducts such as 8-OHdG; the FAPy-G and FAPy-A adducts can also be detected.
Several studies were identified that evaluated the ability of SO to induce DNA strand breakage. The in vitro studies are summarized as follows. As a part of their development of an alkaline elution assay using rat hepatocytes, Sina et al. (1983) used SO as one of their test chemicals. They reported that SO-induced single-strand breaks at concentrations resulting in less than 30% cytotoxicity. SO in vitro exposure caused single-strand DNA breaks (SSBs) in testicular cells both from Wistar rats and from human organ transplant donors using the alkaline elution technique (Bjørge et al., 1996) . Herrero et al. (1997) reported that SO induces SSBs in V79 Chinese hamster cells. Köhlerová and Stetina (2003) treated isolated human peripheral lymphocytes with SO and, based on the Comet assay, determined that DNA strand breaks were induced. They further investigated the removal of these breaks and found that their half-life was about two to four hours. In 2009, Cemeli et al. used lymphocytes from 18 healthy volunteers and treated them with SO (50, 100, and 200 μM; Cemeli et al., 2009 ). The Comet assay was performed on the treated cells, and a positive dose-response effect was observed. Fabiani et al. (2012) treated both freshly isolated peripheral blood mononuclear cells and promyelocytic leukemia cells (HL60) with SO and found DNA breakage based on a positive response in the Comet assay. Godderis et al. (2006) treated peripheral blood mononuclear cells from 20 individuals with SO and, using the Comet assay found a positive response. Isolated peripheral blood mononuclear cells or Tcells, exposed to SO, were positive for the Comet assay (Bausinger and Speit, 2014) . Thus, it seems clear that when mammalian cells are exposed in culture to SO directly, DNA strand breakage can be detected.
We briefly describe two in vivo studies. Vaghef and Hellman (1998) used a single i.p. injection of styrene or SO to expose female B57BL/6 mice. Primary DNA damage was evaluated in several organs using the alkaline Comet assay. The authors reported that both chemicals induced DNA damage in the lymphocytes, liver, bone marrow, and kidney, when the animals were sacrificed and tissue evaluated four hours after exposure. A second time point (16 hr post-treatment) was also evaluated, and the level of DNA damage was decreased in all tissues except the bone marrow cells. This study was conducted prior to the approval of the OECD TG for the in vivo Comet assay, and not all of the details needed to determine if the study was compliant with the TG were included in the publication. However, the fact that the route of exposure was i.p. restricts the utility of the study. Vodicka et al. (2001) exposed male NMRI mice by inhalation using 750 and 1500 mg/m 3 styrene. Mice were exposed six hours per day, seven days per week, for 1, 3, 7, and 21 days. The Comet assay (conducted to measure both breaks and oxidative damage) was used to evaluate double strand DNA breaks (DSBs) in the peripheral lymphocytes, liver, and bone marrow cells. A slight increase in the number of breaks was found in the bone marrow after seven days of inhalation exposure, while a significant increase in the endonuclease III-sensitive sites (a marker for AP sites) was only observed after 21 days. In the liver, no increases were seen after 21 days of inhalation exposure for either strand breaks or endonuclease III-sensitive sites. There was an increase in the lymphocyte strand breaks at 7, but not 21 days.
Weight-of-the-evidence information from primary DNA interactions/damage assays. Styrene/SO exposure results in the formation of both protein and DNA adducts, some of which are chemical-specific and, therefore, are particularly useful to evaluate exposure to styrene. This ability to form adducts has been demonstrated in vitro and in vivo. However, as already emphasized, this does not mean that these adducts result in the induction of gene mutations.
DNA breakage can be evaluated using several techniques. In recent years, the Comet assay has become the most widely used. It is clear that SO exposure induces DNA strand breaks in cultured mammalian cells. The in vivo results for DNA strand breaks following inhalation exposure to styrene are not as clear. Based on the sole inhalation study, DSBs were mostly negative (lymphocytes and liver) and statistically slightly increased only for a single duration and dose (seven-day, high dose) in lymphocytes but not after 1, 3, or 21 days of exposure.
DISCUSSION
The styrene genotoxicity literature originates in the 1970s and includes several hundred publications. These studies coincided with the development of the field of genetic toxicology, and the methods used in the investigations were generally in line with those used in the timeframe in which they were conducted. Many of the early styrene/SO reviews for the genotoxicity literature simply reported the positive/negative calls of the publication authors. This resulted in review authors referencing a large number of studies as positive, providing a perception that there is an extensive literature to indicate that styrene/SO is mutagenic/genotoxic. In addition to providing more weight to positive studies than to negative studies, these reviews included many studies that were conducted using now outdated methods or inadequately described ones.
Critical reviews of the literature, previously provided by several genetic toxicology experts Preston, 1994a, 1994b; Cohen et al., 2002; Speit and Henderson, 2005) , have all concluded that, with the exception of in vitro studies where there is clear evidence that SO is mutagenic/clastogenic, there is no convincing evidence that styrene/SO is mutagenic/clastogenic in vivo in rodents.
In revisiting the mutagenicity/clastogenicity of styrene, we have critically reviewed, based on the recent OECD TG revisions, the literature for the Ames test, gene mutation in mammalian cells, CAs in mammalian cells, MN in mammalian cells, and in vivo rodent studies for CA and MN. Because of changes in methods and data interpretation for the standard genetic toxicology tests, we found much of the published styrene/SO data to be uninterpretable.
We organized our review based on the relative weight that the individual endpoints contribute to the evaluation as to whether a test material can induce mutation. The downside of this approach is that studies conducted using multiple endpoints are divided by endpoint. We think that it is important to highlight a recent study conducted by Gate et al. (2012) that demonstrates an integrated approach to evaluating effects of repeated (four weeks) inhalation (whole body) exposure to styrene and to SO in Fischer 344 rats. Although a discussion of all the details of the paper is beyond the scope of this review, the key results from this study are important to the overall interpretation of the available data on the mutagenicity/clastogenicity of styrene/SO. Rats were exposed to three concentrations of either styrene (75, 300, or 1000 ppm) or SO (25, 50, or 75 ppm) . The frequency of MN in peripheral blood reticulocytes was evaluated by flow cytometry at the end of Day 3 and Day 20 of exposure. This method uses a small sample of tail vein blood, thus allowing for sequential sampling of the same animals (contrary to bone marrow MN analysis). Gate et al. (2012) scored 20,000 cells per animal, resulting in a very high statistical power, whereas the current OECD TG474 (OECD, 2016f) recommends scoring a minimum of 4000 cells, and most older studies scored 1000 to 2000 cells. The Comet assay (both the alkaline and FPG-oxidative damage versions) was also performed on the 3-and 20-day blood samples, which evaluted100 cells (leukocytes) with the Comet Assay IV software and reported percentage of DNA in the Comet tail as the endpoint. The MN assay was clearly negative for all the exposure levels and time points for both the styrene and SO exposures. The alkaline Comet assay evaluating DNA strand breaks in leukocytes found no increases at either time point at any exposure level for both styrene and SO. For the FPG Comet, which assesses oxidative damage, there was a significant increase in the number of DNA breaks in all three styrene exposure groups, but only at the three-day exposure sampling time; no increases were seen at the 20-day sampling. There were no increases in DNA breaks at either time point for the FPG Comet assay following exposure to SO. As previously stated, Comet assay data are not evidence of mutation but of primary DNA damage, which can be repaired. This comprehensive study adds substantially to the weight-of-the-evidence that styrene/SO is not mutagenic/clastogenic in vivo to rodents.
As supporting information, we have included literature for DNA strand breakage (e.g., Comet assay), DNA adducts, protein adducts, and SCEs; all of these are markers of exposure and not evidence of mutation induction.
For our critical review, we applied current recommendations for assay conduct, assay acceptability, and interpretation of data. Based on this approach, we found a large number of the studies to be uninterpretable, but that there were enough reliable/interpretable studies to reach a number of conclusions: (1) Unmetabolized styrene is not mutagenic/clastogenic. For the in vitro test systems, when styrene is metabolized to SO (and the SO is not further metabolized to nongenotoxicants), positive results are obtained.
(2) When SO is the test material, it is clearly mutagenic in the bacterial Ames test. (3) The majority of publications evaluating styrene/SO for gene mutation in cultured mammalian cells were uninterpretable because of major technical deficiencies based on current OECD TGs. A single study using the MLA was, in spite of some technical deficiencies, interpreted to be evidence that SO can induce mutation in cultured mammalian cells. (4) No in vivo studies for the mutagenicity of styrene or SO were identified and, therefore, no conclusions can be made concerning the ability of in vivo styrene/SO exposure to induce gene mutations in the somatic cells of rodents. (5) SO was found to be clastogenic in in vitro mammalian cell assays. (6) Most of the rodent in vivo CA and MN studies could not be interpreted. However, from the few studies that could be interpreted, we conclude that there was no evidence that styrene is clastogenic in vivo and the Gate et al. (2012) study provides strong evidence that neither styrene or SO are clastogenic. (7) Regarding the exposure endpoints, there is evidence that styrene exposure to rodents can result in an increased level of SCEs. SO exposure can result in both chemical-specific and nonchemical-specific DNA adducts in vitro and in vivo in rodents. SO-specific protein adducts have been observed in styrene-exposed rodents. DNA strand breaks are induced in mammalian cells following in vitro exposure to SO.
In conclusion, while SO is clearly mutagenic and clastogenic in vitro, we find no evidence that styrene or SO can induce chromosomal damage in rodents in vivo. We note that there are no in vivo gene mutation studies in rodents.
